Gastroesophageal Reflux Disease Market Analysis

Gastroesophageal Reflux Disease (GERD) Segmentation

Drug Type (Antacids, Proton Pump Inhibitors, H2 Receptor Blocker, Pro Kinetic Agents, Dopamine Receptor Antagonist, EndoCinch, Stretta, EsophyX, Transoral Incisionless, Fundoplication)

The antacids segment value is poised to be the greatest among the others with a market share of 26% by 2036. This is due to the fast relief that antacids provide. It is quick and very effective for all the patients. Antacids are also useful in various conditions which include heartburn, acid indigestion, hyperacidity, upset stomach, and other related illnesses. Furthermore, the growth in the awareness level about self-medication has led to the higher consumption of antacids rather than visiting healthcare systems. In addition to other benefits, antacids deliver fast positive results and have minimal to no side effects, and are even safe for pregnant women. All these factors couple up to create a positive outlook for segment expansion in the next few years.

Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

The hospital pharmacy sub-segment is set to register a significant growth rate in the distribution channel segment in 2036. The major factor projected to help in the growth of the segment size is the rising number of pharmacies in hospitals which increases the ease for the patients visiting hospitals. In addition, the favorable reimbursement policies in hospital pharmacies are also estimated to drive segment size. Also, the presence of trained and qualified staff and the associated trust in the hospitals is anticipated to further help in the expansion of the segment.

Our in-depth analysis of the global market includes the following segments:

Drug Type	Antacids Proton Pump Inhibitors H2 Receptor Blocker Pro Kinetic Agents Dopamine Receptor Antagonist EndoCinch Stretta EsophyX Transoral Incisionless Fundoplication
Route of Administration	Oral Parental
Distribution Channel	Hospital Pharmacy Online Pharmacy Retail Pharmacy
End-Users	Hospital Homecare Specialty Clinics

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of gastroesophageal reflux disease is estimated at USD 5.24 Billion.

The gastroesophageal reflux disease (GERD) market size was over USD 5.12 Billion in 2023 and is anticipated to reach USD 6.88 Billion by 2036, witnessing around 2.3% CAGR during the forecast period i.e., between 2024-2036. Higher consumption of processed food, increase in digestive issues, and problems caused by contaminated food are the few factors likely to propel the market growth.

North America industry is projected to hold 35% of the revenue share in the 2036, owing to rising aging population in the region which are more prone to gastrointestinal problems.

AstraZeneca PLC, Eisai Co., Ltd., GSK plc., Takeda Pharmaceutical Company Limited., Ironwood Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., SFJ Pharmaceuticals, Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., Camber Pharmaceuticals, Inc.

Gastroesophageal Reflux Disease Market Analysis